After establishing that HS-27 treatment was effective on Her2-overexpressing and TNBC cells in vitro, we characterized HS-27 uptake and glycolytic metabolism (using a fluorescent glucose analog, 2-NBDG) in vivo in a human breast cancer xenograft murine window chamber model. Here, ERBB2 is linked to breast cancer.